| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002750 | American Journal of Ophthalmology | 2012 | 10 Pages |
Abstract
Fixed-interval and variable dosing regimens of intravitreal bevacizumab improved visual acuity and anatomic outcomes after 12 months in eyes with neovascular AMD. However, variable dosing had a reduced treatment burden. Larger trials are needed to confirm these results.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Georges M. El-Mollayess, Ziyad Mahfoud, Alexandre R. Schakal, Haytham I. Salti, Dalida Jaafar, Ziad F. Bashshur,